^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    21h
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=430, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Trial completion date: Aug 2031 --> Sep 2030 | Trial primary completion date: Aug 2031 --> Sep 2030
    Enrollment open • Trial completion date • Trial primary completion date • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)
    23h
    A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan (clinicaltrials.gov)
    P2, N=125, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)
    1d
    KisMET-01: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=227, Terminated, Mythic Therapeutics | Trial completion date: Dec 2027 --> Nov 2025 | Recruiting --> Terminated; Business decision
    Trial completion date • Trial termination
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    MYTX-011
    6d
    M24-311: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab (clinicaltrials.gov)
    P2, N=280, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    15d
    A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    29d
    Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer. (PubMed, Acta Oncol)
    These data suggest that c-Met protein OE is associated with MET mRNA expression, shows limited overlap with other MET aberrations, and may be linked to poor prognosis in NSCLC.
    Retrospective data • Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • MET amplification • MET overexpression • MET expression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    1m
    LUMINOSITY: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=270, Active, not recruiting, AbbVie | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR wild-type • MET overexpression • MET expression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    1m
    Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer (clinicaltrials.gov)
    P1, N=30, Terminated, Regeneron Pharmaceuticals | Phase classification: P1/2 --> P1 | Trial completion date: Oct 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Oct 2025; Sponsor decision
    Phase classification • Trial completion date • Trial termination • Trial primary completion date
    |
    MET overexpression
    |
    Libtayo (cemiplimab-rwlc) • REGN5093-M114
    2ms
    HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles. (PubMed, Mol Cancer Ther)
    In summary, HRA00129-C004 is a superior c-Met ADC with relatively low affinity to c-Met, efficient internalization, and strong bystander effect. It is currently being investigated in a Phase I clinical trial for patients with advanced solid tumors.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    HRA00129-C004
    2ms
    First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=310, Recruiting, VelaVigo Bio Inc | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    3ms
    A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan (clinicaltrials.gov)
    P2, N=125, Not yet recruiting, AbbVie
    New P2 trial • Adverse events
    |
    telisotuzumab adizutecan (ABBV-400)